Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Free Report) SVP Andrea Loewen sold 3,175 shares of Reata Pharmaceuticals stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $172.03, for a total value of $546,195.25. Following the sale, the senior vice president now directly owns 28,416 shares in the […]
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Free Report)’s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $170.83 and last traded at $170.83, with a volume of 25211 shares. The stock had previously closed at $170.32. Analysts Set New Price Targets Several brokerages have issued reports […]
Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $172.00 price target on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 1.73% from the company’s previous close. […]
Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating in a note issued to investors on Friday, FlyOnTheWall reports. RETA has been the subject of several other reports. Stifel Nicolaus lowered Reata Pharmaceuticals from a “buy” rating to a “hold” rating in a report on […]
Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report) had its price target boosted by investment analysts at Cantor Fitzgerald from $110.00 to $145.00 in a research note issued to investors on Monday, FlyOnTheWall reports. Cantor Fitzgerald’s price objective would suggest a potential upside of 30.80% from the stock’s current price. Other research analysts have also recently […]